Greater efficacy prediction Leave it to smart scientists to come up with innovations for clinical tracking and measurement.
Korea happens to be one of the potential geographies for licensing the stem cell tech. A collaboaration with this Korean team may prove quite useful.
However, when the hEPCs with outstanding blood vessel regeneration capability are used as stem cell therapy in ischemic diseases, the therapeutic treatment efficacy may differ depending on various variables such as survival of the transplanted cells and migration to the treatment region. Accordingly, treatments for ischemic diseases are remaining in the clinical stage without being commercialized due to the limitations in accurately observing and predicting the therapeutic efficacy.
The Korea Institute of Science and Technology (KIST)recently announced that the collaborative research team led by Dr. Kwangmeyung Kim from Center for Theragnosis and Sung-Hwan Moon from Stem Cell Research Institute, T&R Biofab Co. Ltd developed a method that can predict the therapeutic efficacy based on the distribution of the initial transplantation of hEPCs by tracking the initial distribution and migration of the transplanted cells using fluorescence romographic images.
7 days ago — Hence, these cells can be developed into stem cell therapy for diseases related to blood vessels including ischemic diseases.